October 31, 2017—Thirteen U.S. Senators have asked the Department of Health and 
Human Services to stop delaying enforcement of a 340B drug discount program final rule to police drug manufacturer overcharging.
“HHS has conducted several rounds of public comment and had more than seven years to consider” the 340B ceiling price and manufacturer civil monetary penalties final regulation, the lawmakers said in an Oct. 27 letter to Acting HHS Secretary Eric Hargan and Health Resources and Services Administration Administrator George Sigounas.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)